AOAC SPIFAN Stakeholder Program Meeting Book (March 17, 2021)

STAKEHOLDER PANEL ON INFANT FORMULA & ADULT NUTRITIONALS (SPIFAN) A2 BETA-CASEIN Jeffrey Shippar 1 , Quang Son Pham 2 1 EurofinsUS, Madison WI, USA 2 Abbott Nutrition, Columbus OH, USA Meeting Location March 17, 2021

Call to Action

Situation • New players entering A2 space - fragmenting mkt, increasing competition • At least 3 SPIFAN manufacture have infant formula products w/ A2 claims on store shelves • No clear definition of A2 milk – various testing approaches: genetic and protein What it means • No analyte definition and standard method leaves A2 claims open to interpretation, vulnerable to accusations, disputes • Immediate risk to infant formula products already on market • High potential for disputes between infant formula manufactures and suppliers Why it matters • Significant, urgent threat to brand equity for infant formula industry • Protect consumers through delivering accurate information How to respond • Mitigate risks by developing SMPR, standardizing method through AOAC-SPIFAN What is needed from SPIFAN stakeholders • Active participation from subject matter experts in WG and SMPR development

2